Form 4: Aclaris Therapeutics Chief Scientific Officer Reports Stock Transactions

Aclaris Therapeutics' Chief Scientific Officer, Joseph Monahan, reported the acquisition and disposal of company stock and restricted stock units.

Summary

• Joseph Monahan, Chief Scientific Officer of Aclaris Therapeutics, reported several transactions involving the company's stock.
• On December 31, 2024, Monahan acquired 73,750 shares of common stock through the vesting of restricted stock units and disposed of 32,937 shares to cover tax obligations.
• On January 2, 2025, Monahan acquired 17,380 shares of common stock through the vesting of restricted stock units and disposed of 8,914 shares for tax obligations.
• Monahan also acquired 52,667 restricted stock units on January 2, 2025, which vest over three years.
• Following these transactions, Monahan directly owns 221,062 shares of common stock and indirectly owns 193 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself. It reflects standard compensation practices.

Industry Context

This is a routine filing related to stock transactions by a company insider, which is common practice for publicly traded companies. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transactions reported are typical for executives who receive stock-based compensation, such as restricted stock units.
• The vesting schedules and tax withholding practices are also common in the industry.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect the vesting of previously granted equity compensation.
• The transactions do not have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Aclaris Therapeutics, ACRS, insider trading, stock transactions, restricted stock units, Joseph Monahan, Chief Scientific Officer, Form 4, SEC filing